Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4 May 08, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

may continue. See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

VAGELOS P ROY

2. Issuer Name and Ticker or Trading

Symbol

REGENERON

PHARMACEUTICALS INC

[REGN]

(Last)

(First) (Middle) 3. Date of Earliest Transaction

(Month/Day/Year)

05/06/2013

5. Relationship of Reporting Person(s) to

OMB

Number:

Expires:

response...

Issuer

(Check all applicable)

Chairman of the Board

_X__ Director X_ Officer (give title

10% Owner Other (specify

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

below)

777 OLD SAW MILL RIVER ROAD

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

TARRYTOWN, NY 10591

(City)	(State)	(Zip) Tab	le I - No	on-I	Derivative (Secur	ities Acqui	red, Disposed of,	or Beneficial	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (Instr.		4. Securit onor Dispos (Instr. 3, 4	ed of (` ′	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/08/2013		G	V	1,254	D	\$ 0	161,403	I	by CLAT
Common Stock	04/04/2013		G	V	1,215	D	\$ 0	160,188	I	by CLAT
Common Stock	05/06/2013		S		12,750	D	\$ 263.15 (1)	114,750	I	by Spouse as Trustee
Common Stock	05/06/2013		S		732	D	\$ 264.19	114,018	I	by Spouse as Trustee

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

(2)

Common Stock	56,946	D	
Common Stock	82,410	I	by GRAT
Common Stock	2,352	I	By 401(k) Plan
Common Stock	15,162	I	by GRAT
Common Stock	3	I	by GRAT
Common Stock	1,203	I	by trust for grandch (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
VAGELOS P ROY	X		Chairman of the Board					
777 OLD SAW MILL RIVER ROAD								

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

TARRYTOWN, NY 10591

Signatures

/s/**P. Roy Vagelos

05/08/2013

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents volume-weighted average price of sales of 12,018 shares of Company stock on May 6, 2013 at prices ranging from \$263.00 to (1) \$263.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 6, 2013 at each separate price.
- Represents volume-weighted average price of sales of 732 shares of Company stock on May 6, 2013 at prices ranging from \$264.12 to (2) \$264.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 6, 2013 at each separate price.
- (3) By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3